此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Cesarean Study: Optimizing Cesarean Sections and Improving Patient-Healthcare Provider Trust Using Evidence Informed Recommendations (CS)

2026年8月6日 更新者:Lund University

The Cesarean Study

Cesarean section (CS) rates have rapidly increased worldwide, with projections suggesting that by 2030, one in every three births will be by CS (1). In Sweden, rates have more than doubled from 9% in the 1990s, to 20% in 2024 (2). While CS can be a life-saving procedure when medically indicated, non-essential CS increase the risk of complications and have been linked to increased maternal morbidity and even death, neonatal respiratory issues, and longer recovery times (3). They also place added strain on already burdened healthcare systems by increasing the use of medical resources and staff capacity.

The purpose of this project is to evaluate the use of the "Cesarean Bundle", a three-part intervention designed to improve patient-clinician communication and trust.

Primary Aim: To evaluate the impact of the "Cesarean Bundle" in improving patient-clinician communication and trust compared to standard care.

Hypothesis: Use of the "Cesarean Bundle" will improve patients' trust in their healthcare providers.

Secondary Aim: To evaluate whether adoption of the "Cesarean Bundle" is associated with changes in cesarean section rates, especially among low-risk obstetric populations.

Hypothesis: Implementation of the "Cesarean Bundle" will be associated with a reduction in overall cesarean section rates, particularly among low-risk pregnancies.

研究概览

地位

招聘中

条件

详细说明

Rising CS rates globally and across Europe pose a growing challenge to maternal-newborn health (1). In some European countries, CS rates have soared to 55%, and in Sweden, almost 20,000 procedures are performed annually, with numbers continuing to rise (2, 3). Strikingly, nearly 40% of these are planned cesareans, highlighting a critical need to change on-going clinical practices, especially for low-risk pregnancies, which are well-known drivers of CS rates (5, 6). These rates also contradict the World Health Organization's (WHOs) recommendations that CS rates above 10-15% are not associated with improved maternal-newborn outcomes (5). The WHO has provided clear guidance for reducing non-essential CS (5, 6), emphasizing evidence-based strategies such as requiring a second clinician's sign-off and fostering multidisciplinary reflection, both of which are key parts of the Cesarean study's intervention.

Qualitative evidence from Kingdon et al. (7,8) has shown that women want their birth preferences acknowledged, value individualized information, and are influenced by how health professionals communicate, making shared decision-making essential. However, studies from Quebec (9) and Spain (10) revealed that there are some persistent barriers to implementing guidelines, such as fragmented care and inconsistent messaging, which reinforce the well-known "know-do gap" where best practices fail to reach routine care. The Cesarean Study responds directly to this need, testing a three-part therapy bundle aligned with WHOs recommendations for maximal impact.

Population Pregnant women remitted to clinicians for planned CS discussion.

Intervention

The "Cesarean Bundle", a three-part, decision-support model, comprising of:

I. The Cesarean Discussion Guide, which is a structured clinical tool designed to facilitate personalized, evidence-based conversations between clinicians and patients considering planned cesarean birth. It captures key clinical data, patient values, and birth preferences, integrates risk stratification using the Robson Classification (11-13), and presents short- and long-term outcomes of cesarean versus vaginal birth in a clear, visual format. By standardizing counseling and embedding shared decision-making into routine care, the guide supports more equitable, informed, and patient-centered birth planning. The principal investigator (MZ) has developed the guide with support from Ariadne Labs, Boston USA.

II. Mandatory second opinion/team decision from another clinician for all planned cesarean requests; and, III. Regular team audits reviewing decision-making patterns.

Standard care, consisting of usual clinical consultations for discussing and approving planned CS, without structured guidance or required secondary clinician or team review.

Outcomes Primary outcome Patient-reported trust in the care team, measured by the Health Care Relationship Trust Scale-Revised (HCRTS-R) (14)

Secondary outcomes i) Change in planned CS rate before and after intervention, including subdivisions by Robson Groups for risk stratification ii) Composite of severe neonatal outcomes, including perinatal mortality, 5-min Apgar score <6, hypoxic ischemic encephalopathy grade II-III, intracranial hemorrhage, neonatal seizures, neonatal infection, hypoglycemia, respiratory distress, umbilical arterial pH< 7.05 iii) Composite of severe maternal outcomes, including postpartum hemorrhage (>1000ml), ICU admission, postpartum infection iv) Twelve question survey for clinicians and patients reporting experience of usability, acceptability, feasibility of intervention vs standard care v) Qualitative interviews using the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, and Maintenance) (15) to evaluate the impact and real-world applicability of the Cesarean Bundle across patient, partner, clinician, and system levels vi) Cost-analysis of intervention vs standard care.

研究类型

介入性

注册 (估计的)

260

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

描述

Inclusion Criteria:

  • Pregnant women aged ≥18 years
  • Referred for consultation regarding planned cesarean section
  • Able to provide informed consent (with interpreter support if needed)

Exclusion Criteria:

  • Women with an absolute medical indication for cesarean section (e.g., placenta previa), where shared decision-making is not applicable
  • Women who decline participation in the study components (e.g., surveys/interviews)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Intervention: Cesarean Bundle
Cesarean Bundle (structured discussion guide, mandatory second/team opinion, and regular team reviews/audits)

The Cesarean Bundle is a structured, three-component clinical intervention designed to support evidence-based and shared decision-making for planned cesarean sections:

  1. Cesarean Discussion Guide:

    A standardized decision-support tool used during all consultations for planned cesarean section. It incorporates clinical data, risk stratification (e.g., Robson classification), and clear information on short- and long-term risks and benefits of cesarean versus vaginal birth, while also capturing patient preferences and values.

  2. Mandatory Second/team Opinion:

    All requests for planned cesarean section require review and approval by a second clinician/team before a final decision is made.

  3. Regularl Multidisciplinary Team Meetings:

Regular team-based reviews of cases and decision-making patterns to promote consistency, reflection, and adherence to evidence-based practice.

The intervention is integrated into routine care, with minimal disruption to standard workflows, and is support

无干预:Control Arm
Standard care (usual clinical practice without structured tools)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Patient-Reported Trust in the Care Team
大体时间:Pilot: 12-18 months; Actual study 48 months
Patient-Reported Trust in the Care Team Measured using the Health Care Relationship Trust Scale-Revised (HCRTS-R), a validated questionnaire assessing patients' trust in their healthcare providers following consultation for planned cesarean section. Each of the survey's 13 items is scored individually on a five-point scale (0 to 4), where the item score reflects the patient's immediate assessment of specific relational experiences, such as active listening, truth-telling, and respect for privacy. After converting one reverse-worded question to ensure that higher numbers consistently reflect stronger alignment with positive relational attributes, the individual item scores are summed to generate a cumulative total score ranging from 0 to 52. Within this spectrum, the higher the score, the better the reported trust and communication.
Pilot: 12-18 months; Actual study 48 months

次要结果测量

结果测量
措施说明
大体时间
Cesarean section rates
大体时间:Pilot: 12-18 months. Actual study: 48-54 months as some cesarean section may be reported at later date after the pregnancy has led to the birth of the baby.
Using Robson Groups
Pilot: 12-18 months. Actual study: 48-54 months as some cesarean section may be reported at later date after the pregnancy has led to the birth of the baby.
Maternal outcome
大体时间:Pilot: 12-18 months. Main study: 48-54 months as some maternal outcomes may be reported at later date after the pregnancy has led to the birth of the baby.
This is a composite of whether any of the following maternal outcomes was found (Y/N): postpartum hemorrhage (> or = 1000 ml), admission to intensive care unit (ICU) admission, and postpartum infection needing antiobiotics.
Pilot: 12-18 months. Main study: 48-54 months as some maternal outcomes may be reported at later date after the pregnancy has led to the birth of the baby.
Neonatal outcome
大体时间:Pilot: 12-18 months. Actual study: 48-54 months depending on when data is available from the patient charts and once the pregnancy has led to birth of the baby
This is a composite of whether any of the following neonatal outcomes was present (Y/N): perinatal mortality, 5-minute Apgar score less than 7, hypoxic-ischemic encephalopathy (grade I-III), intracranial hemorrhage, neonatal seizures, infection, hypoglycemia, respiratory distress, and umbilical artery pH <7.05.
Pilot: 12-18 months. Actual study: 48-54 months depending on when data is available from the patient charts and once the pregnancy has led to birth of the baby
Patient-Reported Experience
大体时间:Pilot 12-18 months. Actual study 48-54 months
This is a survey that uses a 12-item questionnaire assessing acceptability, usability, and feasibility of the intervention. Total score 0-12 where 12 is the highest number and indicated best reported experience.
Pilot 12-18 months. Actual study 48-54 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月5日

初级完成 (估计的)

2030年5月15日

研究完成 (估计的)

2035年12月31日

研究注册日期

首次提交

2026年6月26日

首先提交符合 QC 标准的

2026年8月6日

首次发布 (实际的)

2026年8月12日

研究记录更新

最后更新发布 (实际的)

2026年8月12日

上次提交的符合 QC 标准的更新

2026年8月6日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data (IPD) will be shared, including demographic variables (e.g., age, parity, BMI), clinical characteristics (e.g., pregnancy and delivery data, indication for cesarean section), intervention exposure, and outcome measures (e.g., planned cesarean rates, maternal and neonatal outcomes, and patient-reported trust scores).

Survey responses (e.g., HCRTS-R and acceptability/feasibility questionnaires) and relevant implementation metrics may also be included. All data will be pseudonymized, with direct identifiers removed, in accordance with GDPR and applicable data protection regulations.

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅